News

• 3 Nov, 2023
  Spago Nanomedical delårsrapport januari-september 2023
• 3 Nov, 2023
  Spago Nanomedical interim report January-September 2023
• 31 Oct, 2023
  Kommuniké från extra bolagsstämma i Spago Nanomedical AB den 31 oktober 2023
• 31 Oct, 2023
  Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB on 31 October 2023
• 24 Oct, 2023
  Spago Nanomedical ansöker om utökat patentskydd för Tumorad®
• 24 Oct, 2023
  Spago Nanomedical applies for extended patent protection for Tumorad®
• 19 Oct, 2023
  Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien
• 19 Oct, 2023
  Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia
• 5 Oct, 2023
  Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ)
• 5 Oct, 2023
  Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ)